Download Poster

A Phase 1b, Dose-escalation Study of QR-010, a Novel Antisense Oligonucleotide Administered in Subjects with Cystic Fibrosis Homozygous for the F508del CFTR Mutation

Useful links

You are now leaving ProQR Therapeutics

ProQR Therapeutics provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by ProQR Therapeutics, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL